Browse all Canadian datasets
Browse the complete CanQuery catalogue, including downloadable files, live tables and maps.
Open datasets
- Guidance Document For Clinical Trial Sponsors: Clinical Trial Applications
- Notice to Stakeholders – Clarification of Requirements Under the Food and Drug Regulations When Conducting Clinical Research With Cannabis
- Draft Guidance for Industry: Preparation of Comparative Bioavailability Information for Drug Submissions in the CTD Format
- Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies
- Notice: Clarification of bioanalytical method validation procedures
- Summary: Guidance Document - Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs
- Revised Guidance Document: Acetaminophen Labelling Standard
- Info Source: Sources of Federal Government and Employee Information
- Prohibitions related to scientific research and clinical applications
- Prohibitions related to Surrogacy
- Consent to Use Human Reproductive Material and In Vitro Embryos
- Toward a strengthened Assisted Human Reproduction Act
- Reimbursing a sperm or ova (egg) donor or a surrogate for expenditures related to donation or surrogacy
- Reporting a complaint for the Assisted Human Reproduction Act
- Inspection approach for blood establishments (POL-0039)
- Prohibitions related to Purchasing Reproductive Material and Purchasing or Selling In Vitro Embryos
- Notice: Policy on Bioequivalence Standards for Highly Variable Drug Products
- Notice: Guidance Document - Data Requirements for Safety and Effectiveness of Subsequent Entry Inhaled Corticosteroid Products Used for the Treatment of Asthma
- Guidance Document - Human-Use Antiseptic Drugs
- Mandatory reporting of serious adverse drug reactions and medical device incidents by hospitals - Overview
- Guidance Document for Source Establishments - Reporting Adverse Reactions to Human Cells, Tissues and Organs
- Donating and using third-party sperm or ova (eggs) for assisted human reproduction
- Compliance and Enforcement: Assisted Human Reproduction
- Blood for transfusion or for use in the manufacture of a drug
- Myths and facts - plasma donation
- Plasma Donation in Canada
- Blood Establishment Licensing Application Form and Instructions - (FRM-0354)
- Blood Establishment Registration Application: Form and Instructions - (FRM-0353)
- Guidance Document: Blood Regulations
- Wading Pools
- Canada's National Forest Inventory (NFI) 2006
- COVID-19: Readiness criteria and indicators for easing restrictive public health measures
- National Advisory Committee on Immunization (NACI): Summary of extended dose interval statement of April 7, 2021
- Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply
- Vaccines for COVID-19: What to expect at your vaccination
- Government of Canada establishes Critical Drug Reserve to bolster Canada’s supply of drugs used to treat COVID-19
- Interim Order No. 2 Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19
- Government of Canada announces funding to help reduce stigma and support families affected by the overdose crisis
- COVID-19 clinical trials IO and clinical trials records retention: Consultation report
- Explanatory note on new interim order to advance COVID-19 clinical trials
- Addressing vaccine hesitancy in the context of COVID-19: A primer for health care providers
- Components of COVID-19 vaccines authorized by Health Canada
- Laboratory guidance for SARS-CoV-2 testing
- Modelling approach to assessing risk of transmission of SARS-CoV-2 at gatherings
- COVID-19 negative patients who retested positive
- Influenza vanishing following COVID-19 measures, Hamilton, ON
- COVID-19: Application of the Quarantine Act Border Measures (ArriveCAN 2) (July 2020)
- 2021–22 Departmental Plan: Health Canada
- Federal actions on opioids to date
- Helping people who use substances during the COVID-19 pandemic